After Hours Summary: AVGO jumps +12.1% on earnings and 10-for-1 stock split; PLAY -8.7%, OXM -2.7% lower on earnings; JILL -16% falls on stock offering
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: AVGO +12.1% (also announces 10-for-1 stock split), CURV +5.5% (also announces new COO), PLCE +2.7%
Companies trading higher in after hours in reaction to news: WRB +2% (declares $0.50/sh special dividend, increases regular dividend, approves a 3-for-2 stock split), MRVL +1.2% (in sympathy with strong AVGO earnings), NVDA +0.7% (in sympathy with strong AVGO earnings), CPA +0.7% (reports May traffic), RTX +0.6% (awarded $293 mln US Special Ops Command contract), JPM +0.4% (analyst conference presentation), CLLS +0.4% (unveils a gene therapy approach for Sickle Cell Disease in Nature Comms), SNPS +0.1% (in sympathy with strong AVGO earnings), WFG +0.1% (increases dividend), MSFT +0.1% (OpenAI's annualized revs double since late 2023, according to The Information), GE +0.1% (awarded $1.13 bln U.S. Army contract), ETRN +0.1% (Mountain Valley Pipeline preparing $7.85 bln pipe from WV to VA to operate following US regulatory approval, according to Reuters)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: PLAY -8.7% (also executes sale leaseback agreement of two properties for $45 mln), OXM -2.7%
Companies trading lower in after hours in reaction to news: JILL -16% (2 mln share offering), PLNT -4.8% (completes previously announced refinancing transaction), PLAB -4.4% (CAO placed on administrative leave during ongoing internal review), RARE -1.9% (to file for accelerated approval of UX111 for MPS IIIA), VERI -1.9% (files $300 mln mixed shelf securities offering), ARES -1.1% (launches 2.65 mln share offering), COHR -0.6% (ships its 300-millionth optical transceiver from Malaysia facility), AZN -0.6% (FDA approves FARXIGA for pediatric type-2 diabetes), RNA -0.4% ($300 mln stock offering), DOMO -0.4% (enlisted by Fluxx to streamline intelligence), SWKS -0.1% (in sympathy with strong AVGO earnings), PFE -0.1% (Phase 3 Study of gene therapy for DMD did not meet its primary endpoint )